Kristie A. Bobolis

Dr. Kristie A. Bobolis

Hematology
8 Medical Plaza Drive, Suite 300, 
Roseville, CA 
On Staff At
Offers Telehealth
8 Medical Plaza Drive, Suite 300, 
Roseville, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kristie Bobolis is a Hematologist in Roseville, California. Dr. Bobolis is rated as an Experienced provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, Follicular Lymphoma, and Gastroesophageal Junction Cancer.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of California, Irvine
Residency
University of California, Los Angeles Medical Center
Specialties
Hematology
Licenses
Internal Medicine in CA
Board Certifications
Hematology Medical Oncology
Fellowships
Duke University Medical Center
Hospital Affiliations
Sutter Medical Center, Sacramento
Sutter Roseville Medical Center
Sutter Auburn Faith Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Roseville Medical Plaza Care Center
8 Medical Plaza Drive, Suite 300, Roseville, CA 95661

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib
Enrollment Status: Active_not_recruiting
Publish Date: October 29, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 20, 2025
Intervention Type: Drug, Procedure, Radiation, Other
Study Drug: Olaparib
Study Phase: Phase 2
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 02, 2025
Intervention Type: Other, Biological, Procedure, Drug, Radiation, Device
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 2/Phase 3
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
EndoPredict® Extended Endocrine Trial (EXET): A Prospective Registry to Evaluate the Impact of EndoPredict® Test on Extended Endocrine Treatment Decisions and Patient Outcomes.
Enrollment Status: Terminated
Publish Date: May 17, 2022
Intervention Type: Other
View 7 Less Clinical Trials

9 Total Publications

Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
Journal: medRxiv : the preprint server for health sciences
Published: March 18, 2024
Similar Doctors
Advanced in Hemochromatosis
Dr. Michael P. Carroll
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Michael P. Carroll
Hematology Oncology | Hematology | Oncology
2750 Gateway Oaks Dr, Suite 150, 
Sacramento, CA 
 (17.7 miles away)
Languages Spoken:
English
See accepted insurances

Michael Carroll is a Hematologist Oncology specialist and a Hematologist in Sacramento, California. Dr. Carroll is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

Advanced in Hemochromatosis
Dr. Rashmi Ramasubbaiah
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. Rashmi Ramasubbaiah
Hematology Oncology | Hematology | Oncology
3102 Porte Morino Drive, Suite 100, 
Cameron Park, CA 
 (16.5 miles away)
530-323-6600
Languages Spoken:
English, Hindi, Kannada, Telugu
See accepted insurances

Rashmi Ramasubbaiah is a Hematologist Oncology specialist and a Hematologist in Cameron Park, California. Dr. Ramasubbaiah is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. Her top areas of expertise are Paget Disease of the Breast, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Angiosarcoma.

Advanced in Hemochromatosis
Dr. William E. Bonis
Hematology Oncology | Hematology | Oncology
Advanced in Hemochromatosis
Dr. William E. Bonis
Hematology Oncology | Hematology | Oncology

Marshall Medical Center

3581 Palmer Dr, Suite 400, 
Cameron Park, CA 
 (16.8 miles away)
530-676-6600
Languages Spoken:
English, Bahasa, French, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

William Bonis is a Hematologist Oncology specialist and a Hematologist in Cameron Park, California. Dr. Bonis is rated as a Distinguished provider by MediFind in the treatment of Hemochromatosis. His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Chronic B-Cell Leukemia (CBCL), and Non-Hodgkin Lymphoma. Dr. Bonis is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bobolis's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile